These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin. Atil B; Berger-Sieczkowski E; Bardy J; Werner M; Hohenegger M Naunyn Schmiedebergs Arch Pharmacol; 2016 Jan; 389(1):17-32. PubMed ID: 26319048 [TBL] [Abstract][Full Text] [Related]
28. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Hoque A; Chen H; Xu XC Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):88-94. PubMed ID: 18199714 [TBL] [Abstract][Full Text] [Related]
29. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors. Alfon J; Guasch JF; Berrozpe M; Badimon L Atherosclerosis; 1999 Aug; 145(2):325-31. PubMed ID: 10488960 [TBL] [Abstract][Full Text] [Related]
30. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin. Bergstrom JD; Bostedor RG; Rew DJ; Geissler WM; Wright SD; Chao YS Biochim Biophys Acta; 1998 Jan; 1389(3):213-21. PubMed ID: 9512650 [TBL] [Abstract][Full Text] [Related]
31. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Han KH; Ryu J; Hong KH; Ko J; Pak YK; Kim JB; Park SW; Kim JJ Circulation; 2005 Mar; 111(11):1439-47. PubMed ID: 15781755 [TBL] [Abstract][Full Text] [Related]
32. HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation. Al-Haidari AA; Syk I; Thorlacius H Biochem Biophys Res Commun; 2014 Mar; 446(1):68-72. PubMed ID: 24582560 [TBL] [Abstract][Full Text] [Related]
33. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. Morikawa S; Umetani M; Nakagawa S; Yamazaki H; Suganami H; Inoue K; Kitahara M; Hamakubo T; Kodama T; Saito Y J Atheroscler Thromb; 2000; 7(3):138-44. PubMed ID: 11480454 [TBL] [Abstract][Full Text] [Related]
34. Cytotoxicity of Simvastatin in Human Breast Cancer MCF-7 and MDA-MB-231 Cell Lines. Rezano A; Ridhayanti F; Rangkuti AR; Gunawan T; Winarno GNA; Wijaya I Asian Pac J Cancer Prev; 2021 Feb; 22(S1):33-42. PubMed ID: 33576210 [TBL] [Abstract][Full Text] [Related]
35. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. Wilcox LJ; Barrett PH; Huff MW J Lipid Res; 1999 Jun; 40(6):1078-89. PubMed ID: 10357840 [TBL] [Abstract][Full Text] [Related]
37. Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. Thunyakitpisal PD; Chaisuparat R J Pharmacol Sci; 2004 Apr; 94(4):403-9. PubMed ID: 15107580 [TBL] [Abstract][Full Text] [Related]
38. Simvastatin, a potent HMG-CoA reductase inhibitor, inhibits the proliferation of human and bovine endothelial cells in vitro. Sato I; Ma L; Ikeda M; Morita I; Murota S J Atheroscler Thromb; 1998; 4(3):102-6. PubMed ID: 9730140 [TBL] [Abstract][Full Text] [Related]
39. Effect of simvastatin on castration-resistant prostate cancer cells. Kim JH; Cox ME; Wasan KM Lipids Health Dis; 2014 Mar; 13():56. PubMed ID: 24666612 [TBL] [Abstract][Full Text] [Related]
40. Determination of simvastatin-derived HMG-CoA reductase inhibitors in biomatrices using an automated enzyme inhibition assay with radioactivity detection. Liu L; Zhang R; Zhao JJ; Rogers JD; Hsieh JY; Fang W; Matuszewski BK; Dobrinska MR J Pharm Biomed Anal; 2003 Apr; 32(1):107-23. PubMed ID: 12852453 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]